Nanoscale Reports

RESEARCH ARTICLE

DOI:10.26524/nr.8.9

8(2) (2025) 13-15

OPEN ACCESS

AI-guided design of nanocarriers for targeted drug delivery in tumors

Dimple M.D[a]*

Abstract

Targeted drug delivery represents a critical advancement in cancer treatment, offering improved efficacy and minimized systemic toxicity. Nanocarriers have emerged as promising vehicles for site-specific delivery of anticancer drugs due to their customizable physicochemical properties. However, designing nanocarriers capable of effective tumor targeting remains a complex challenge, given the diverse variables involved in tumor biology, drug kinetics, and nanoparticle interactions with biological environments. The integration of artificial intelligence (AI) into the nanocarrier design process is transforming the landscape of drug delivery research. This article explores the use of AI, particularly machine learning and deep learning models, in guiding the rational design of nanocarriers for tumor-targeted drug delivery. A framework is proposed for utilizing AI tools to optimize design parameters, predict biological interactions, and improve formulation outcomes, thus accelerating the development of effective cancer therapies.

Keywords: Artificial Intelligence, Nanocarriers, Targeted Drug Delivery, Tumor, Machine Learning, Deep Learning, Nanomedicine, Cancer Therapy, Ligand Targeting, Nanoparticle Design

Author Affiliation: [a] Department of Microbiology, Maharani's Science College, Mysore, India.

Corresponding Author: Dimple M.D., Department of Microbiology, Maharani's Science College, Mysore, India.

Email: dimplemd8@gmail.com

How to cite this article: Dimple M.D, AI-guided design of nanocarriers for targeted drug delivery in tumors, Nanoscale Reports, 8(2) 2025 13-15. Retrieved from https://nanoscalereports.com/index.php/nr/article/view/110

Received: 13 January 2024 Revised: 12 Mayl 2025 Accepted: 20 June 2025

I.INTRODUCTION

Cancer remains one of the most pressing global health issues, with conventional treatment strategies often limited by systemic side effects and low therapeutic indices [1]. Targeted drug delivery aims to address these limitations by selectively directing therapeutic agents to tumor cells while sparing healthy tissues [2]. Nanocarriers, including liposomes, polymeric nanoparticles, dendrimers, and micelles, offer a versatile platform for this purpose due to their ability to be engineered for size, shape, surface properties, and functionalization [3].

Despite their potential, the successful translation of nanocarrier-based therapies to clinical settings is constrained by the complex and variable nature of tumor microenvironments, the unpredictability of in vivo behavior, and the vast design space of possible nanomaterial combinations [4]. These challenges call for advanced methodologies that can efficiently process large datasets, recognize hidden patterns, and generate predictive models for nanocarrier behavior [5]. Artificial intelligence, particularly its subfields of machine learning and deep learning, is emerging as a powerful tool in this domain, enabling data-driven decisions that improve design accuracy and therapeutic performance [6].

2. THE ROLE OF AI IN NANOCARRIER DESIGN

AI techniques facilitate the integration and analysis of diverse datasets generated from experimental studies, biological databases, and high-throughput screenings [7]. By identifying complex nonlinear relationships between nanocarrier features and biological outcomes, AI models can support the optimization of design parameters that are otherwise difficult to assess manually [8].

Machine learning algorithms are employed to correlate physicochemical characteristics—such as particle size, surface charge, and hydrophobicity—with key delivery metrics like circulation time, tumor accumulation, and intracellular uptake [9]. Supervised learning models can be trained on labeled datasets from prior experiments to predict the efficacy of new nanocarrier formulations [10]. In parallel, unsupervised learning approaches can help cluster nanoparticle types based on performance and uncover hidden trends across experimental conditions [11].

Deep learning, with its capacity for representation learning, enhances this process by handling high-dimensional data from imaging, genomics, and molecular simulations [12]. Neural networks, particularly convolutional and recurrent architectures, are capable of learning abstract features related to nanoparticle-tumor interactions, including cellular uptake dynamics, endosomal escape, and degradation pathways [13]. These models assist in evaluating how nanocarriers behave under different biological conditions and in various tumor types [14].

An essential application of AI in nanocarrier design is the prediction of ligand-receptor interactions [15]. Functionalization of nanoparticles with targeting ligands aims to enhance specificity by binding to overexpressed receptors on tumor cells [16]. AI models can evaluate large ligand libraries and predict binding affinities using molecular structure data and docking simulations [17]. This accelerates the identification of ligands

with high targeting potential, reducing the need for labor-intensive experimental validation [18].

3. AI Framework for Rational Nanocarrier Design

A comprehensive AI-based design framework for nanocarriers begins with data collection and curation, including experimental data, literature reports, and biological databases relevant to tumor types and drug delivery performance [19]. These data are processed to extract meaningful features such as physicochemical parameters, pharmacokinetic profiles, and tumor characteristics [20].

The next stage involves the construction of predictive models using machine learning or deep learning techniques [21]. These models are trained to associate design features with outcomes such as tumor accumulation, biodistribution, cytotoxicity, and immune response [22]. Once validated, the models can predict the performance of new or hypothetical nanocarrier designs prior to synthesis and testing [23].

Optimization algorithms are then applied to iteratively refine candidate designs based on predicted performance metrics [24]. This feedback loop allows researchers to converge on optimal formulations with higher probabilities of success in preclinical or clinical studies [25]. In addition, incorporating explainable AI methods helps researchers understand the influence of each feature on the model's prediction, enhancing transparency and interpretability of the results [26].

4. CHALLENGES AND FUTURE DIRECTIONS

While the integration of AI in nanocarrier design shows significant promise, several limitations must be addressed to fully realize its potential [27]. One major challenge is the scarcity and heterogeneity of high-quality, annotated datasets that are critical for training reliable models [28]. Biological systems are inherently complex, and the generalizability of AI predictions across different tumor types or biological models remains a concern [29].

Another challenge is the interpretability of deep learning models [30]. Although these models offer superior predictive capabilities, their "black-box" nature makes it difficult to extract mechanistic insights that are vital in biomedical research [31]. Developing more transparent models and adopting explainability tools will be crucial for fostering trust in AI-driven recommendations, particularly in clinical contexts [32].

Future research should focus on creating standardized, open-access databases of nanoparticle formulations and their biological performance [33]. Advances in multi-omics data integration and personalized medicine will further enhance the ability of AI to tailor nanocarrier designs to individual patients [34]. Combining AI with automated synthesis platforms and high-throughput screening will also streamline the iterative development cycle, accelerating the translation of AI-guided nanomedicine into real-world therapies [35].

5. CONCLUSION

AI is poised to play a transformative role in the design of nanocarriers for targeted cancer therapy. By enabling the analysis of complex, high-dimensional data, AI facilitates more informed and efficient decisions in nanoparticle formulation. This data-driven approach not only enhances the precision of drug delivery systems but also significantly reduces time and cost associated with experimental trials. As AI tools mature and integrate seamlessly with experimental workflows, the future of personalized, effective nanomedicine becomes increasingly attainable.

Acknowledgemet

Nill

Funding

No funding was received to carry out this study.

References

1. Kolluri, V. (2024). Revolutionizing healthcare delivery: The role of AI and machine learning in personalized medicine and predictive analytics. Well Testing Journal, 33(S2), 591-618.
2. Yarlagadda, V. S. T. (2020). AI and Machine Learning for Optimizing Healthcare Resource Allocation in Crisis Situations. International Transactions in Machine Learning, 2(2).
3. Chinthala, L. K. (2021). Revolutionizing business operations with nanotechnology: A strategic perspective. Nanoscale Reports, 4(3), 23–27. https://nanoscalereports.com/index.php/nr
4. Kolluri, V. (2016). Machine Learning in Managing Healthcare Supply Chains: How Machine Learning Optimizes Supply Chains, Ensuring the Timely Availability of Medical Supplies. International Journal of Emerging Technologies and Innovative Research, 2349-5162.
5. Gatla, T. R. (2024). AI-driven regulatory compliance for financial institutions: Examining how AI can assist in monitoring and complying with ever-changing financial regulations.
6. Kolluri, V. (2021). A Comprehensive Study on AI-powered Drug Discovery: Rapid Development of Pharmaceutical Research. International Journal of Emerging Technologies and Innovative Research, 2349-5162.
7. Yarlagadda, V. S. T. (2017). AI-Driven Personalized Health Monitoring: Enhancing Preventive Healthcare with Wearable Devices. International Transactions in Artificial Intelligence, 1(1).
8. Kolluri, V. (2024). Cybersecurity Challenges in Telehealth Services: Addressing the security vulnerabilities and solutions in the expanding field of telehealth. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(1), 23-33.
9. Gatla, T. R. (2020). AN IN-DEPTH ANALYSIS OF TOWARDS TRULY AUTONOMOUS SYSTEMS: AI AND ROBOTICS: THE FUNCTIONS. IEJRD-International Multidisciplinary Journal, 5(5), 9.
10. Yarlagadda, V. S. T. (2018). AI for Healthcare Fraud Detection: Leveraging Machine Learning to Combat Billing and Insurance Fraud. Transactions on Recent Developments in Artificial Intelligence and Machine Learning, 10(10).
11. Kolluri, V. (2015). A Comprehensive Analysis on Explainable and Ethical Machine: Demystifying Advances in Artificial Intelligence. TIJER–TIJER–INTERNATIONAL RESEARCH JOURNAL, ISSN, 2349-9249.
12. Yarlagadda, V. S. T. (2022). AI and Machine Learning for Improving Healthcare Predictive Analytics: A Case Study on Heart Disease Risk Assessment. Transactions on Recent Developments in Artificial Intelligence and Machine Learning, 14(14).
13. Kolluri, V. (2024). Revolutionary research on the AI sentry:

an approach to overcome social engineering attacks using machine intelligence. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(1), 53-60.
14. Gatla, T. R. (2023). MACHINE LEARNING IN CREDIT RISK ASSESSMENT: ANALYZING HOW MACHINE LEARNING MODELS ARE.
15. Kolluri, V. (2024). An Extensive Investigation Into Guardians Of The Digital Realm: AI-Driven Antivirus And Cyber Threat Intelligence. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(2), 71-77.
16. Yarlagadda, V. S. T. (2019). AI-Enhanced Drug Discovery: Accelerating the Development of Targeted Therapies. International Scientific Journal for Research, 1(1).
17. Gatla, T. R. (2024). An innovative study exploring revolutionizing healthcare with AI: personalized medicine: predictive diagnostic techniques and individualized treatment. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(2), 61-70.
18. Kolluri, V. (2024). THE IMPACT OF MACHINE LEARNING ON PATIENT DIAGNOSIS ACCURACY: INVESTIGATING.
19. Kolluri, V. (2024). An in-depth exploration of unveiling vulnerabilities: exploring risks in AI models and algorithms. IJRAR-International Journal of Research and Analytical Reviews, E-ISSN, 2348-1269.
20. Yarlagadda, V. S. T. (2024). AI-Driven Early Warning Systems for Critical Care Units: Enhancing Patient Safety. International Journal of Sustainable Development in Computer Science Engineering, 8(8).
21. Kolluri, V. (2016). An Innovative Study Exploring Revolutionizing Healthcare with AI: Personalized Medicine: Predictive Diagnostic Techniques and Individualized Treatment. International Journal of Emerging Technologies and Innovative Research, 2349-5162.
22. Yarlagadda, V. S. T. (2017). AI in Precision Oncology: Enhancing Cancer Treatment Through Predictive Modeling and Data Integration. Transactions on Latest Trends in Health Sector, 9(9).
23. Kolluri, V. (2024). A thorough examination of fortifying cyber defenses: AI in real-time driving cyber defense strategies today. International Journal of Emerging Technologies and Innovative Research, ISSN, 2349-5162.
24. Yarlagadda, V. S. T. (2022). AI and Machine Learning for Optimizing Healthcare Resource Allocation in Crisis Situations. International Transactions in Machine Learning, 2(2).
25. Kolluri, V. (2024). Cutting-edge insights into unmasking malware: AI-powered analysis and detection techniques. International Journal of Emerging Technologies and Innovative Research, ISSN, 2349-5162.
26. Yarlagadda, V. S. T. (2018). AI for Remote Patient Monitoring: Improving Chronic Disease Management and Preventive Care. International Transactions in Artificial Intelligence, 3(3).
27. Gatla, T. R. (2024). A groundbreaking research in breaking language barriers: NLP and linguistics development. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(1), 1-7.
28. Kolluri, V. (2024). Cybersecurity Challenges in Telehealth Services: Addressing the security vulnerabilities and solutions in the expanding field of telehealth. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(1), 23-33.
29. Kolluri, V. (2021). A Comprehensive Study on AI-powered Drug Discovery: Rapid Development of Pharmaceutical Research. International Journal of Emerging Technologies and Innovative Research, 2349-5162.
30. Yarlagadda, V. S. T. (2019). AI-Powered Virtual Health Assistants: Transforming Patient Care and Healthcare Delivery. International Journal of Sustainable Development in Computer Science Engineering, 4(4).
31. Kolluri, V. (2024). Revolutionizing healthcare delivery: The role of AI and machine learning in personalized medicine and predictive analytics. Well Testing Journal, 33(S2), 591-618.
32. Gatla, T. R. (2018). Enhancing Customer Service in Banks with AI Chatbots: The Effectiveness and Challenges of Using AI-Powered Chatbots for Customer Service in the Banking Sector. TIJER-INTERNATIONAL RESEARCH JOURNAL, ISSN, 2349-9249.
33. Kolluri, V. (2024). The role of machine learning in personalized healthcare: Enhancing patient care and outcomes through AI-driven solutions.
34. Yarlagadda, V. S. T. (2024). AI-Driven Early Warning Systems for Critical Care Units: Enhancing Patient Safety. International Journal of Sustainable Development in Computer Science Engineering, 8(8).
35. Chinthala, L. K. (2019). Nanotechnology in Retail: Smart Packaging, Product Longevity, and Consumer Trust. Nanoscale Reports, 2(3), 14-17.